BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Akero’s EFX reverses cirrhosis in MASH patients in phase IIb trial
What a difference 60 weeks can make. That’s the lesson Akero Therapeutics Inc. shared with the rollout of what executives called “unprecedented” data from the phase IIb...

More in BioWorld

BioWorld MedTech

Analysts are optimistic about outlook for med tech in 2025
With multiple large M&A deals already announced in January, CEOs of major med-tech companies outlining acquisition plans for 2025 and declining interest rates, the stage is...

More in BioWorld MedTech

BioWorld Science

Linkgevity targets aging as it joins startup accelerator KQ Labs
Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an...

More in BioWorld Science

BioWorld Asia

Newco Prolium licenses antibody from Innocare, Keymed for $520M
In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody...

More in BioWorld Asia

BioWorld Insider Podcast

The BioWorld Insider podcast is a monthly dive into the business and science of drug development. Conversations with CEOs and BioWorld analysts in the past 12 months have included a wide range of chats with experts who are shaping the future.